Resources.kamsc.org.au
Type II Diabetes
Targets:
• HbA1c ≤7% (53 mmol/mol)**
HbA1c can be used for screening, diagnosis and ongoing
• Lipids: TC<4, TG<2, HDL>1, LDL<1.8 mmol/L
Early detection and glycaemic control can prevent serious
monitoring of diabetes. (See FLOWCHART)
Interpretation of HbA1c:
• BMI <25kg/m2
• All Aboriginal people over 15 years of age.
• Waist Circumference (Female <88cm, Male <100cm)
• Children over 10 years of age with any of the
factors in Box 1 in consultation with Regional
IF ≥5.7% send venous sample to
lab
(see flowchart)
(**note targets may need to be individualized)
• Anyone with impaired glucose tolerance (IGT) (also
What about blood glucose?
Reduce overall CVD risk:
referred to as prediabetes) or at high risk according
If someone has had a diagnostic HbA1c, they do not
• Exercise ≥20min walking ≥4 days per week
to AUSDRISK tool.
need to have an OGTT to confirm their diagnosis.
ype II Diabe
Every 3 years:
If a patient has had a random capillary glucose reading
• Alcohol 2 standard drinks/day maximum
• Non Aboriginal adults over 40 years of age should be
of ≥5.5, then a HbA1c (if not done in last 12 months)
screened with AUSDRISK tool, test as below if score
is suggested to check for potential diabetes. A random
• Dietary modification
capillary glucose reading of ≥12.2 is likely to indicate
diabetes and must be confirmed with a venous HbA1c.
Principles of Management
• Venous* OR point of care (POC) HbA1c. (
*one
• Review non pharmacological management at every
venous sample per year funded by MBS)
See protocol for anyone with
• Before increasing medication carefully review
Box 1 Risk factors for Aboriginal children ≥ 10 years
diabetes or prediabetes.
adherence to existing therapy.
Overweight or obese (>85th Centile BMI)
• Every visit encourage appropriate lifestyle changes.
• If on medications other than metformin ask about
Positive family history
• Offer individual education and dietary consultation
symptoms of hypoglycaemia.
Signs of hyperinsulinism (Acanthosis nigricans/PCOS)
with appropriately trained health professionals.
• Avoid or minimise the use of glycaemic drugs
Oral Hypoglycaemic Agents (OHAs)
Born to a mother with diabetes/gestational diabetes
(thiazides, steroids, psychotropics).
1st line: Metformin commence 500mg daily (XR)/bd.
Pyschotropic therapy
Up titrate to maximum 2g total daily over four weeks.
(
From Azzopardi et al, MJA 2012)
Maximum daily dose Metformin
UEC, LFTs, TSH, Lipid
Waist circumference
Retinal Screening
NB Metformin should be WITHELD in sepsis, MI, critical
*ideally fasted, but not essential – label fasting vs non fasting
illness or prior to contrast administration.
Kimberley Aboriginal Medical Services Council (KAMSC) and WA Country Health Service (WACHS) Kimberley
VC - Last Modified: August 10, 2015 10:42 AM
Type II Diabetes
2nd line: ADD one of:
• Targets: morning fasting glucose of <6 mmol/L or
• Gliclazide MR: 30mg MR daily, double dose every 4
non-fasting glucose levesl <8 mmol/L.
• Retinal screening, full foot check, ECG, lipids profile.
weeks to maximum 120mg daily, monitor for hypos.
• Isophane insulin (Protaphane Innolet) may be
• Ensure influenza and pneumococcal vaccines are up
• Sitagliptin 100mg daily. (NB also available as 50mg
considered as an alternative, discuss with Regional
and 100mg strength combined with 1000mg XR
Women of child bearing age
NB: These agents will need to be reduced with declining
Exenatide can be considered as an alternative second
line agent in patients with BMI >25 and normal renal
function who are willing to consider bd subcutaneous
If pregnancy is being contemplated:
eGFR 45-60 => reduce dose as GFR declines below
• Aim for HbA1c <6% before conception.
60, monitor for hypos
This agent can be used in combination with insulin, but
• Commence folic acid 5mg daily (note higher dose).
eGFR<45=> cease
doses of both agents need to be adjusted cautiously. Seek
• Pregnancy accelerates diabetic retinopathy. Conduct
input from the Regional Physicians.
retinal screening if a normal screen has not been
eGFR 30-50ml/min => 50mg once daily
documented in last 12 months.
eGFR <30ml/min => 25mg once daily
Cease sitagliptin if commencing exenatide.
ype II Diabe
If pregnancy is not being contemplated:
IF patient remains above target on either of these, then the
How to start:
• Ensure reliable form of contraception is being used.
alternate 2nd line OHA may be added as a third agent.
• Commence at 5mcg daily, increase to 5mcg bd after
2-4 weeks if tolerated. Uptitrate in 5mcg intervals to
total 10mcg bd. Review GI side effects before each
If HbA1c is extremely high (eg ≥ 12% (108 mmol/mol)),
insulin is the only agent proven to reduce glycaemia to
Regional Physician Team
target. Therefore, it can be considered as part of first line
• Monitor renal function.
Ensure 3 monthly follow up investigations up to date at time
• Advise patient before commencement to report
therapy in that context.
of appointment.
Alternatively, insulin should be added if not at target on
abdominal pain. Check lipase and consider
• Inadequate control of diabetes despite maximum
maximal oral therapy.
pancreatitis in this scenario.
• Consider alternative agents if ineffective at six
• Total dose of insulin 100 units/day without improved
Education required about: Insulin storage, administration
glycaemic control.
and monitoring (especially for hypoglycaemia).
Follow up
• Unexplained hypoglycaemic episodes, multiple
How to start:
complications and/or comorbidities.
3 monthly
• Any questions about exenatide.
Glargine insulin (Lantus)
Ask about medicines, symptoms of coronary artery
• Continue OHAs at same dose.
• Commence at 10 units subcutaneously at the same
protocol), diet, smoking and exercise.
• Check weight, BP, waist circumference, feet (See foot
• Review at least weekly and monitor for
• Pathology: HbA1c, UEC, LFTs, Urine ACR.
• Increase dose by 2-4 units as often as every three
days until glycaemic targets met.
Kimberley Aboriginal Medical Services Council (KAMSC) and WA Country Health Service (WACHS) Kimberley
VC - Last Modified: August 10, 2015 10:42 AM
Type II Diabetes
FOOT CARE
POC machine available?
Perform foot examination at baseline and annually,
and stratify according to risk as below. If LOW risk –
examine annually (does NOT need to see podiatrist).
If HIGH risk – examine 3 monthly AND refer to see
POC capillary HbA test
(< 39 mmol/mol)
(≥ 39 mmol/mol)
Present (or Hx of)
Foot deformity /
ype II Diabe
Take venous blood for laboratory HbA test
(same day if possible)
(< 39 mmol/mol)
(≥ 48 mmol/mol)
rescreen in 12 months
(follow diabetes protocol)
(follow diabetes protocol)
Give healthy lifestyle advice, see
Kimberley Aboriginal Medical Services Council (KAMSC) and WA Country Health Service (WACHS) Kimberley
VC - Last Modified: August 10, 2015 10:42 AM
Source: http://resources.kamsc.org.au/downloads/cd_dtii.pdf
En el 2010 escribimos esto y firmamos muchas organizaciones de Latinoamerica Caribe "Desde diversos lugares de América Latina y el Caribe, nosotras, algunas de las organizaciones y personas participantes del VIII ELFLAC Encuentro Lésbico Femi- nista Latinoamericano y del Caribe realizado en octubre de 2010 en Guatemala, queremos hacer públicas nuestras reflexiones colectivas sobre el mismo, y sobre
Case report of oral melanoma in a king penguin (Aptenodytes patagonicus) found by cooperation between Kosei Inui1, Miyuki Hamaguchi1, Satomi Yonezawa1, Makiko Nishizawa1, Takeshi Wada1, Kazutoshi Takami2 1: Naniwa-Hone-Hone-Dan, Osaka Museum of Natural History 2: Osaka Municipal Tennoji Zoological Gardens AZEC 2013, Fukuoka King penguin (Aptenodytes patagonicus)